Directly Reprogrammed NK Cells Driven by BCL11B Depletion Enhance Targeted Immunotherapy against Pancreatic Ductal Adenocarcinoma

Scientists presented a synergistic immunotherapy platform that integrates natural killer reprogramming, CAR engineering, and tumor sensitization. The combinatorial approach significantly enhances antitumor efficacy in PDAC and offers a promising strategy for overcoming immune resistance in solid tumors.